SecBot SecBot

CORT drug pipeline

CORCEPT THERAPEUTICS INC · 4 rated drugs
$72.94
−1.0% 1-day · Nov 13
Next catalyst
Dec 17, 2026
Lifyorli PDUFA date · in 31 days
Typical move on FDA news
±10.4%
1-day, median of 9 events
IV rank
58
IV 101% · HV 81%
Rated drugs
4
1 bullish · 1 mixed · 2 neutral
Phase 3 trials
0
0 with results posted

Upcoming catalysts

2 dated
  1. Dec 17, 202631d
    Lifyorli
    PDUFA date · Cushing's syndrome
  2. Dec 2026
    Lifyorli
    Phase 2 primary completion

Drugs

soonest catalyst first
▲ bullish
Impact
PhaseApproved
Time to marketLifyorli is already approved and commercially available in the U.S. for platinum-resistant ovarian cancer (approved March 25, 2026). A decision on the Cushing's syndrome indication is expected by December 17, 2026. A Marketing Authorization Application (MAA) is also under review by the European Medicines Agency.

Lifyorli relacorilant Updated Nov 5

31days
Next catalyst
PDUFA date · Dec 17, 2026 · Cushing's syndrome
What to watch

The next major catalyst is the December 17, 2026 PDUFA decision on relacorilant's NDA resubmission for Cushing's syndrome. An approval would open a large endocrinology market (currently served by Korlym, which generated ~$498M in the first nine months of 2026) and could significantly expand the drug's total addressable market beyond the already-approved ovarian cancer indication. A second CRL would be a major setback for the Cushing's franchise.

Bull case
  • Lifyorli is the first and only FDA-approved selective glucocorticoid receptor antagonist (SGRA), a novel mechanism that enhances chemotherapy sensitivity by blocking cortisol signaling in tumor cells.
  • The drug's commercial launch is accelerating rapidly: Q3 2026 Lifyorli revenue was $91.4 million, up 92% from $47.6 million in Q2 2026, with total company revenue of $340.5 million beating analyst estimates.
  • The pivotal ROSELLA Phase 3 trial showed a 35% reduction in risk of death, and the regimen was added to NCCN Guidelines as a preferred treatment option.
Bear case
  • The FDA issued a Complete Response Letter (CRL) for relacorilant in Cushing's syndrome in December 2025, and the resubmission may face similar concerns about the GRACE trial data or liver safety signals.
  • Insiders have been selling substantial amounts of stock in October and November 2026, with multiple executives exercising options and selling shares at prices between $80-$116.
  • The stock has fallen sharply from its 52-week high of $126.38 to $71.63, a decline of over 43%, suggesting significant de-risking or concerns about the Cushing's PDUFA outcome.
● neutral
Impact
PhasePhase 2
Time to marketAt least 3-5 years away, if ever. Miricorilant is in Phase 2 development. A Phase 3 program has not yet been initiated, and no regulatory filings have been submitted. The drug is not the company's lead asset.

miricorilant Updated Nov 5

What to watch

Miricorilant's Phase 2b MONARCH results were just released (Nov 3, 2026) and are now a known event. The next catalyst is the planned Phase 2 study at higher doses, but no date has been set. For Corcept investors, the more immediate binary catalyst is the relacorilant PDUFA on December 17, 2026. Miricorilant remains an early-stage pipeline asset; positive MONARCH data de-risks the mechanism somewhat, but the drug is years away from any regulatory decision.

Bull case
  • MONARCH Phase 2b results showed dose-dependent reductions in liver fat and a 19% fibrosis improvement rate on biopsy at 48 weeks, with adverse events similar to placebo, suggesting a favorable safety profile at low doses (100-200 mg twice weekly).
  • The MASH/NASH market is a multi-billion-dollar opportunity with no FDA-approved therapies for NASH with fibrosis, so positive data could position miricorilant as a first-in-class treatment.
  • Corcept has strong commercial execution (Q3 2026 revenue of $340.5M, up 64% YoY) and a deep pipeline, providing financial resources to advance miricorilant without near-term dilution risk.
Bear case
  • An earlier Phase 2 NASH trial (NCT03823703) using higher miricorilant doses (600-900 mg) was terminated due to abnormal laboratory values, raising safety questions that will need to be addressed at higher doses.
  • The MONARCH results are from a Phase 2b study, not a pivotal Phase 3 trial. The path to registration is long and uncertain, with no guarantee that efficacy will replicate in larger, longer studies.
  • The MASH/NASH field is littered with failed late-stage trials (e.g., Intercept's Ocaliva, Genfit's elafibranor), making it a high-risk therapeutic area.
◆ mixed
Impact
PhasePhase 2 (completed)
Time to marketPhase 3 has not yet begun (planned for 2027). If Phase 3 succeeds, potential FDA submission would be several years away, likely 2029-2030 at the earliest.

dazucorilant Updated Nov 5

What to watch

Dazucorilant's next catalyst is the planned Phase 3 trial initiation, expected in 2027 per the Q3 2026 earnings call. There is no PDUFA or binary readout date on the calendar for this drug within the next 12 months. The main near-term value driver for Corcept is the relacorilant PDUFA for Cushing's syndrome on December 17, 2026, not dazucorilant. Investors should watch for Phase 3 trial design details and enrollment timelines as the next meaningful derisking event.

Bull case
  • Phase 2 data showed an 87% reduction in risk of death at two years for the 300 mg dose versus placebo, a large survival signal in a disease with few treatment options (source: Corcept press release Apr 30, 2026).
  • FDA granted Fast Track Designation, which can accelerate development and review (source: Corcept press release Dec 11, 2024).
  • Corcept is a well-capitalized commercial-stage company with $662.3M in cash and $340.5M in quarterly revenue (+64% YoY), eliminating financing risk for the Phase 3 program (source: Q3 2026 earnings 8-K filed Nov 3, 2026).
Bear case
  • Phase 2 DAZALS study failed its primary endpoint of slowing ALS disease progression (ALSFRS-R decline), a significant red flag (source: Corcept press release Dec 11, 2024).
  • The survival benefit was a secondary endpoint; ALS has a history of promising Phase 2 survival signals failing to replicate in larger Phase 3 trials.
  • Phase 3 has not yet started (planned for 2027), meaning pivotal data are likely 3-5 years away, with no near-term binary catalyst for this drug.
● neutral
Impact
PhasePhase 1b/2
Time to marketIf Phase 1b/2 data are positive (expected end of 2027), a Phase 2 or pivotal trial would follow, putting potential approval several years away, likely 2029 or later.

nenocorilant Updated Nov 5

What to watch

The next catalyst for nenocorilant is Phase 1b dose-finding data from the SYNERGY trial, which Corcept expects by the end of 2027. The stock's near-term binary is the relacorilant PDUFA on December 17, 2026, which will dominate investor attention. Nenocorilant is too early-stage to move the stock independently in the near term.

Bull case
  • Nenocorilant targets a novel mechanism (glucocorticoid receptor antagonism) to overcome resistance to checkpoint inhibitors, potentially addressing a large unmet need in patients who do not respond to PD-1/L1 therapies.
  • Corcept is a profitable, commercial-stage company with $544.6M in cash and investments (June 2026), providing ample funding to advance the SYNERGY trial without dilution risk.
  • The SYNERGY trial uses nivolumab (Opdivo, BMS), a well-established immunotherapy, reducing combination risk versus an unproven partner drug.
Bear case
  • Prior Phase 1b data for ORIC-101 (same molecule) in metastatic prostate cancer showed acceptable tolerability but no clinical benefit when combined with enzalutamide, raising questions about GR antagonism as a cancer strategy.
  • The SYNERGY trial is still recruiting with only 30 planned patients in Phase 1b; early-stage oncology trials have a high failure rate.
  • Nenocorilant is a tiny part of Corcept's pipeline; the company's value is driven by approved products Korlym and Lifyorli and the upcoming relacorilant PDUFA, not this early-stage asset.

Other drugs in filings and trials

no drug report yet
  • KORLYM Last: Approval · Feb 17, 2012
  • mifepristone 1 trial

Past FDA events & how the stock moved

9 events
DateDrugEvent1 day5 days
Jul 11, 2026LifyorliPDUFA decision−6.5%−1.5%
Jul 11, 2026LifyorliOrphan drug designation−6.5%−1.5%
Apr 30, 2026LifyorliApproval+10.4%+9.6%
Apr 14, 2026LifyorliOrphan drug designation+1.4%+4.2%
Apr 13, 2026LifyorliApproval+4.2%+10.6%
Mar 25, 2026LifyorliApproval+13.9%+24.1%
Jan 22, 2026LifyorliOrphan drug designation+21.1%+22.9%
Dec 30, 2025LifyorliPDUFA decision−56.4%−53.6%
Feb 17, 2012KORLYMApproval+54.5%+44.1%

Clinical trials

4 Phase 2/3
DrugTrialPhaseStatusEnrolledPrimary completion
LifyorliExtension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing SyndromePhase 2Active not recruiting125Dec 2026
miricorilantA Phase 2b, Study Evaluating Miricorilant in Adult Patients With Nonalcoholic Steatohepatitis/Metabolic Dysfunction-Associated Steatohepatitis (MONARCH)Phase 2Completed175Feb 13, 2026
ExicorilantStudy to Evaluate Exicorilant (CORT125281) in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate CancerPhase 2Terminated · results39Oct 13, 2021
mifepristoneA Study on the Efficacy of 10 mg Oral Mifepristone for the Treatment of Symptomatic Uterine LeiomyomasPhase 2Terminated—Not stated